B-cell aortic homing and atheroprotection depend on Id3

Circulation Research

Volumn 110, Issue 1, 2012, Pages

  Doran, Amanda C ^a,b   Lipinski, Michael J ^a,b   Oldham, Stephanie N ^a,b   Garmey, James C ^a,b   Campbell, Kirsti A ^a,b   Skaflen, Marcus D ^a,b   Cutchins, Alexis ^a,b   Lee, Daniel J ^a   Glover, David K ^a,b   Kelly, Kimberly A ^a,c   Galkina, Elena V ^a,e   Ley, Klaus ^f   Witztum, Joseph L ^g   Tsimikas, Sotirios ^g   Bender, Timothy P ^d   McNamara, Coleen A ^a,b  

^a UNIVERSITY OF VIRGINIA   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

^c University of Virginia   (United States)

^d Department of Biomedical Engineering ^*  (United States)

^e EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

^f LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY   (United States)

^g UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

atherosclerosis; B lymphocytes; helix loop helix; homing; transcription factors

Indexed keywords

CHEMOKINE RECEPTOR CCR6; INHIBITOR OF DIFFERENTIATION 3;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; AORTA; ARTICLE; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; B LYMPHOCYTE; BLOOD; BONE MARROW CELL; CELL HOMING; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DISEASE COURSE; FLOW CYTOMETRY; HEART PROTECTION; IMAGING; LYMPH NODE; MACROPHAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN;

ANIMALS; AORTA; APOLIPOPROTEINS E; ATHEROSCLEROSIS; B-LYMPHOCYTES; CELL MOVEMENT; DIET; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; INCIDENCE; INHIBITOR OF DIFFERENTIATION PROTEINS; MICE; MICE, KNOCKOUT; PLAQUE, ATHEROSCLEROTIC; RECEPTORS, CCR6; SIGNAL TRANSDUCTION;

EID: 84855340806     PISSN: 00097330     EISSN: 15244571     Source Type: Journal    
DOI: 10.1161/CIRCRESAHA.111.256438     Document Type: Article

References (40)

1. Lusis AJ. Atherosclerosis. Nature. 2000;407:233-241.
2. Libby P. Inflammation in atherosclerosis. Nature. 2002;420:868-874. (Pubitemid 36019640)
3. Hansson GK, Hermansson A. The immune system in atherosclerosis. Nat Immunol. 2011;12:204-212.
4. Galkina E, Ley K. Immune and inflammatory mechanisms of atherosclerosis. Annu Rev Immunol. 2009;27:165-197.
5. Grabner R, Lotzer K, Dopping S, Hildner M, Radke D, Beer M, Spanbroek R, Lippert B, Reardon CA, Getz GS, Fu YX, Hehlgans T, Mebius RE, van der Wall M, Kruspe D, Englert C, Lovas A, Hu D, Randolph GJ, Weih F, Habenicht AJ. Lymphotoxin beta receptor signaling promotes tertiary lymphoid organogenesis in the aorta adventitia of aged ApoE-/-mice. J Exp Med. 2009;206:233-248.
6. Moos MP, John N, Grabner R, Nossmann S, Gunther B, Vollandt R, Funk CD, Kaiser B, Habenicht AJ. The lamina adventitia is the major site of immune cell accumulation in standard chow-fed apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol. 2005;25:2386-2391. (Pubitemid 41552659)
7. Schwartz CJ, Mitchell JR. Cellular infiltration of the human arterial adventitia associated with atheromatous plaques. Circulation. 1962;26: 73-78.
8. Aubry MC, Riehle DL, Edwards WD, Maradit-Kremers H, Roger VL, Sebo TJ, Gabriel SE. B-Lymphocytes in plaque and adventitia of coronary arteries in two patients with rheumatoid arthritis and coronary atherosclerosis: preliminary observations. Cardiovasc Pathol. 2004;13: 233-236. (Pubitemid 38798365)
9. Higuchi ML, Gutierrez PS, Bezerra HG, Palomino SA, Aiello VD, Silvestre JM, Libby P, Ramires JA. Comparison between adventitial and intimal inflammation of ruptured and nonruptured atherosclerotic plaques in human coronary arteries. Arq Bras Cardiol. 2002;79:20-24.
10. Houtkamp MA, de Boer OJ, van der Loos CM, van der Wal AC, Becker AE. Adventitial infiltrates associated with advanced atherosclerotic plaques: structural organization suggests generation of local humoral immune responses. J Pathol. 2001;193:263-269. (Pubitemid 32118139)
11. Watanabe M, Sangawa A, Sasaki Y, Yamashita M, Tanaka-Shintani M, Shintaku M, Ishikawa Y. Distribution of inflammatory cells in adventitia changed with advancing atherosclerosis of human coronary artery. J Atheroscler Thromb. 2007;14:325-331.
12. Yla-Herttuala S, Palinski W, Butler SW, Picard S, Steinberg D, Witztum JL. Rabbit and human atherosclerotic lesions contain IgG that recognizes epitopes of oxidized LDL. Arterioscler Thromb. 1994;14:32-40.
13. Zhou X, Hansson GK. Detection of B cells and proinflammatory cytokines in atherosclerotic plaques of hypercholesterolaemic apolipoprotein E knockout mice. Scand J Immunol. 1999;50:25-30. (Pubitemid 29298023)
14. Galkina E, Kadl A, Sanders J, Varughese D, Sarembock IJ, Ley K. Lymphocyte recruitment into the aortic wall before and during development of atherosclerosis is partially L-selectin dependent. J Exp Med. 2006;203:1273-1282. (Pubitemid 43736596)
15. Caligiuri G, Nicoletti A, Poirier B, Hansson GK. Protective immunity against atherosclerosis carried by B cells of hypercholesterolemic mice. J Clin Invest. 2002;109:745-753. (Pubitemid 34263151)
16. Major AS, Fazio S, Linton MF. B-lymphocyte deficiency increases atherosclerosis in LDL receptor-null mice. Arterioscler Thromb Vasc Biol. 2002;22:1892-1898. (Pubitemid 35315778)
17. Kee BL, Murre C. Induction of early B cell factor (EBF) and multiple B lineage genes by the basic helix-loop-helix transcription factor E12. J Exp Med. 1998;188:699-713. (Pubitemid 28387933)
18. Pan L, Sato S, Frederick JP, Sun XH, Zhuang Y. Impaired immune responses and B-cell proliferation in mice lacking the Id3 gene. Mol Cell Biol. 1999;19:5969-5980. (Pubitemid 29399302)
19. Li H, Dai M, Zhuang Y. A T cell intrinsic role of Id3 in a mouse model for primary Sjogren's syndrome. Immunity. 2004;21:551-560. (Pubitemid 39370510)
20. Taylor AM, Li F, Thimmalapura P, Gerrity RG, Sarembock IJ, Forrest S, Rutherford S, McNamara CA. Hyperlipemia and oxidation of LDL induce vascular smooth muscle cell growth: an effect mediated by the HLH factor Id3. J Vasc Res. 2006;43:123-130. (Pubitemid 43247993)
21. Doran AC, Lehtinen AB, Meller N, Lipinski MJ, Slayton RP, Oldham SN, Skaflen MD, Yeboah J, Rich SS, Bowden DW, McNamara CA. Id3 is a novel atheroprotective factor containing a functionally significant single-nucleotide polymorphism associated with intima-media thickness in humans. Circulation research. 2010;106:1303-1311.
22. Kitamura D, Roes J, Kuhn R, Rajewsky K. A B cell-deficient mouse by targeted disruption of the membrane exon of the immunoglobulin mu chain gene. Nature. 1991;350:423-426. (Pubitemid 21912244)
23. Daugherty A, Whitman SC. Quantification of atherosclerosis in mice. Methods Mol Biol. 2003;209:293-309.
24. Galkina E, Harry BL, Ludwig A, Liehn EA, Sanders JM, Bruce A, Weber C, Ley K. CXCR6 promotes atherosclerosis by supporting T-cell homing, interferon-gamma production, and macrophage accumulation in the aortic wall. Circulation. 2007;116:1801-1811. (Pubitemid 350287105)
25. Hayakawa I, Tedder TF, Zhuang Y. B-lymphocyte depletion ameliorates Sjogren's syndrome in Id3 knockout mice. Immunology. 2007;122:73-79. (Pubitemid 47222597)
26. Tsimikas S, Brilakis ES, Lennon RJ, Miller ER, Witztum JL, McConnell JP, Kornman KS, Berger PB. Relationship of IgG and IgM autoantibodies to oxidized low density lipoprotein with coronary artery disease and cardiovascular events. J Lipid Res. 2007;48:425-433. (Pubitemid 46220609)
27. Ait-Oufella H, Herbin O, Bouaziz JD, Binder CJ, Uyttenhove C, Laurans L, Taleb S, Van Vré E, Esposito B, Vilar J, Sirvent J, Van Snick J, Tedgui A, Tedder TF, Mallat Z. B cell depletion reduces the development of atherosclerosis in mice. J Exp Med. 2010;207:1579-1587.
28. Kyaw T, Tay C, Khan A, Dumouchel V, Cao A, To K, Kehry M, Dunn R, Agrotis A, Tipping P, Bobik A, Toh BH. Conventional B2 B cell depletion ameliorates whereas its adoptive transfer aggravates atherosclerosis. J Immunol. 2010;185:4410-4419.
29. Kyaw T, Tay C, Krishnamurthi S, Kanellakis P, Agrotis A, Tipping P, Bobik A, Toh BH. B1a B lymphocytes are atheroprotective by secreting natural IgM that increases IgM deposits and reduces necrotic cores in atherosclerotic lesions. Circ Res. 2011;109:830-840.
30. Lipinski MJ, Perry HM, Doran AC, Oldham SN, McNamara CA. Comment on "Conventional B2 B cell depletion ameliorates whereas its adoptive transfer aggravates atherosclerosis." J Immunol. 2011;186:4.
31. Campbell JJ, Butcher EC. Chemokines in tissue-specific and microenvironment-specific lymphocyte homing. Curr Opin Immunol. 2000;12:336-341. (Pubitemid 30240545)
32. Wan W, Lim JK, Lionakis MS, Rivollier A, McDermott DH, Kelsall BL, Farber JM, Murphy PM. Genetic deletion of chemokine receptor Ccr6 decreases atherogenesis in ApoE-deficient mice: novelty and significance. Circ Res. 2011;109:374-381.
33. Schutyser E, Struyf S, Van Damme J. The CC chemokine CCL20 and its receptor CCR6. Cytokine Growth Factor Rev. 2003;14:409-426. (Pubitemid 37099454)
34. McDonald KG, McDonough JS, Wang C, Kucharzik T, Williams IR, Newberry RD. CC chemokine receptor 6 expression by B lymphocytes is essential for the development of isolated lymphoid follicles. Am J Pathol. 2007;170:1229-1240. (Pubitemid 47339331)
35. Murre C. Helix-loop-helix proteins and lymphocyte development. Nat Immunol. 2005;6:1079-1086. (Pubitemid 41541785)
36. Caligiuri G, Khallou-Laschet J, Vandaele M, Gaston AT, Delignat S, Mandet C, Kohler HV, Kaveri SV, Nicoletti A. Phosphorylcholinetargeting immunization reduces atherosclerosis. J Am Coll Cardiol. 2007; 50:540-546.
37. Nicoletti A, Kaveri S, Caligiuri G, Bariety J, Hansson GK. Immunoglobulin treatment reduces atherosclerosis in apo E knockout mice. J Clin Invest. 1998;102:910-918. (Pubitemid 28419236)
38. Tsimikas S, Bergmark C, Beyer RW, Patel R, Pattison J, Miller E, Juliano J, Witztum JL. Temporal increases in plasma markers of oxidized lowdensity lipoprotein strongly reflect the presence of acute coronary syndromes. J Am Coll Cardiol. 2003;41:360-370. (Pubitemid 36164488)
39. Zhou X, Caligiuri G, Hamsten A, Lefvert AK, Hansson GK. LDL immunization induced T-cell-dependent antibody formation and protection against atherosclerosis. Arterioscler Thromb Vasc Biol. 2001;21: 108-114. (Pubitemid 32061934)
40. Fraley AE, Schwartz GG, Olsson AG, Kinlay S, Szarek M, Rifai N, Libby P, Ganz P, Witztum JL, Tsimikas S. Relationship of oxidized phospholipids and biomarkers of oxidized low-density lipoprotein with cardiovascular risk factors, inflammatory biomarkers, and effect of statin therapy in patients with acute coronary syndromes: results from the MIRACL (Myocardial Ischemia Reduction With Aggressive Cholesterol Lowering) Trial. J Am Coll Cardiol. 2009;53:2186-2196.